Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

医学 吉西他滨 恶心 内科学 粘膜炎 危险系数 呕吐 胃肠病学 不利影响 临床终点 临床研究阶段 置信区间 化疗 外科 肿瘤科 随机对照试验
作者
Chigusa Morizane,Takuji Okusaka,Junki Mizusawa,Hiroshi Katayama,Makoto Ueno,Masafumi Ikeda,Masato Ozaka,Naohiro Okano,Kazuya Sugimori,Akira Fukutomi,Hiroki Hara,Nobumasa Mizuno,Hiroaki Yanagimoto,Keita Wada,Kazutoshi Tobimatsu,Kei Yane,Shoji Nakamori,Hiroyuki Yamaguchi,Akinori Asagi,Seigo Yukisawa,Yasushi Kojima,Ken Kawabe,Yasuyuki Kawamoto,Rie Sugimoto,Tomohisa Iwai,Kazuyoshi Nakamura,Hiroyoshi Miyakawa,Tatsuya Yamashita,A. Hosokawa,Tatsuya Ioka,Naoya Kato,Kazuhiko Shioji,Kyoko Shimizu,Toshio Nakagohri,Ken Kamata,Hiroshi Ishii,Junji Furuse
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:30 (12): 1950-1958 被引量:248
标识
DOI:10.1093/annonc/mdz402
摘要

BackgroundGemcitabine plus cisplatin (GC) is the standard treatment of advanced biliary tract cancer (BTC); however, it causes nausea, vomiting, and anorexia, and requires hydration. Gemcitabine plus S-1 (GS) reportedly has equal to, or better, efficacy and an acceptable toxicity profile. We aimed to confirm the non-inferiority of GS to GC for patients with advanced/recurrent BTC in terms of overall survival (OS).Patients and methodsWe undertook a phase III randomized trial in 33 institutions in Japan. Eligibility criteria included chemotherapy-naïve patients with recurrent or unresectable BTC, an Eastern Cooperative Oncology Group Performance Status of 0 − 1, and adequate organ function. The calculated sample size was 350 with a one-sided α of 5%, a power of 80%, and non-inferiority margin hazard ratio (HR) of 1.155. The primary end point was OS, while the secondary end points included progression-free survival (PFS), response rate (RR), adverse events (AEs), and clinically significant AEs defined as grade ≥2 fatigue, anorexia, nausea, vomiting, oral mucositis, or diarrhea.ResultsBetween May 2013 and March 2016, 354 patients were enrolled. GS was found to be non-inferior to GC [median OS: 13.4 months with GC and 15.1 months with GS, HR, 0.945; 90% confidence interval (CI), 0.78–1.15; P = 0.046 for non-inferiority]. The median PFS was 5.8 months with GC and 6.8 months with GS (HR 0.86; 95% CI 0.70–1.07). The RR was 32.4% with GC and 29.8% with GS. Both treatments were generally well-tolerated. Clinically significant AEs were observed in 35.1% of patients in the GC arm and 29.9% in the GS arm.ConclusionsGS, which does not require hydration, should be considered a new, convenient standard of care option for patients with advanced/recurrent BTC.Clinical Trial numberThis trial has been registered with the UMIN Clinical Trials Registry (http://www.umin.ac.jp/ctr/index.htm), number UMIN000010667.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
ED应助ouyggg采纳,获得10
2秒前
Tomsen发布了新的文献求助50
2秒前
人生苦短完成签到,获得积分10
4秒前
氪金读书完成签到,获得积分10
4秒前
Nami应助sylnd126采纳,获得10
4秒前
4秒前
儒雅致远发布了新的文献求助30
4秒前
4秒前
4秒前
yyy完成签到,获得积分20
5秒前
abala完成签到,获得积分10
5秒前
小二郎应助飞天817采纳,获得10
5秒前
Quinna发布了新的文献求助20
7秒前
yyy发布了新的文献求助30
8秒前
8秒前
abala发布了新的文献求助30
8秒前
郭小宝发布了新的文献求助10
8秒前
9秒前
科研通AI2S应助任性蘑菇采纳,获得10
9秒前
嘿嘿发布了新的文献求助10
9秒前
sundial发布了新的文献求助10
9秒前
10秒前
莫乞完成签到,获得积分10
10秒前
11秒前
我是老大应助木象爱火锅采纳,获得10
12秒前
13秒前
shuang0116发布了新的文献求助10
13秒前
ZJH发布了新的文献求助10
13秒前
14秒前
独角兽完成签到,获得积分10
14秒前
15秒前
NexusExplorer应助儒雅致远采纳,获得10
15秒前
chlgkmoney完成签到 ,获得积分20
15秒前
15秒前
16秒前
852应助科研通管家采纳,获得10
16秒前
wanci应助科研通管家采纳,获得10
16秒前
1111应助科研通管家采纳,获得20
16秒前
快乐的胖子应助科研通管家采纳,获得100
16秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Economic Geography and Public Policy 900
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988786
求助须知:如何正确求助?哪些是违规求助? 3531116
关于积分的说明 11252493
捐赠科研通 3269766
什么是DOI,文献DOI怎么找? 1804771
邀请新用户注册赠送积分活动 881870
科研通“疑难数据库(出版商)”最低求助积分说明 809021